Paul W Jones1,2, Heather Gelhorn3, Hilary Wilson3, Niklas Karlsson4, Shailendra Menjoge5, Hana Müllerova2, Stephen I Rennard6,7, Ruth Tal-Singer8, Debora Merrill9, Maggie Tabberer2. 1. Institute of Infection and Immunity, St George's University of London, United Kingdom. 2. Research and Development, GlaxoSmithKline, Uxbridge, United Kingdom. 3. Evidera, Bethesda, Maryland. 4. Research and Development, AstraZeneca, Gothenburg, Sweden. 5. Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut. 6. Division of Pulmonary, Critical Care, Sleep and Allergy, Nebraska Medical Center, Omaha. 7. Research and Development, AstraZeneca, Cambridge, United Kingdom. 8. Research and Development, GlaxoSmithKline, King of Prussia, Pennsylvania. 9. COPD Foundation, Washington, D.C.
Abstract
Background: Patient-reported outcomes data in clinical trials are usually reported as mean values, interpreted in comparison to a minimum clinically important difference (MCID) and ignoring the possibility of a sizable proportion of patients experiencing a worthwhile benefit when the majority did not. This analysis tested the reliability of calculated responder rates (from chronic obstructive pulmonary disease [COPD] patients) with the St George's Respiratory Questionnaire (SGRQ) using a range of responder cut-points above and below the MCID (4 units). Methods: Individual patient data (i.e., data from long-acting bronchodilator [LAB] and inhaled corticosteroids [ICS]/long-acting beta2-agonist [LABA] randomized clinical studies) in the COPD Biomarker Qualification Consortium database were used: short-term (≤1-year duration; 14,814 patients,) and medium-term (2-4 years; 12,043 patients). Responder rates versus placebo across SGRQ score change thresholds ranging from -1.5 to -8.0 were tested; differences were expressed as the odds ratio (OR) of a patient exceeding the threshold versus no change or deterioration. Results: The ORs measuring benefit of active treatment were similar across thresholds in short-term studies (LAB, ORs 1.40-1.42; LABA/ICS, 1.50-1.56) and medium-term LAB studies (ORs 1.34-1.43), whereas ORs in medium-term studies with LABA/ICS intervention showed a trend for higher response rates at higher values of threshold cut-points (1.64-1.79). In short-term studies, different thresholds had little effect on the OR between active drugs versus a trend for lower ORs with lower thresholds in medium-term studies. Conclusions: The OR for a treatment effect compared with placebo appears consistent across a range of responder cut-points. In medium-term trials, the treatment difference between active drugs suggests that use of a lower threshold would not increase the odds of observing a measured treatment difference.
RCT Entities:
Background: Patient-reported outcomes data in clinical trials are usually reported as mean values, interpreted in comparison to a minimum clinically important difference (MCID) and ignoring the possibility of a sizable proportion of patients experiencing a worthwhile benefit when the majority did not. This analysis tested the reliability of calculated responder rates (from chronic obstructive pulmonary disease [COPD] patients) with the St George's Respiratory Questionnaire (SGRQ) using a range of responder cut-points above and below the MCID (4 units). Methods: Individual patient data (i.e., data from long-acting bronchodilator [LAB] and inhaled corticosteroids [ICS]/long-acting beta2-agonist [LABA] randomized clinical studies) in the COPD Biomarker Qualification Consortium database were used: short-term (≤1-year duration; 14,814 patients,) and medium-term (2-4 years; 12,043 patients). Responder rates versus placebo across SGRQ score change thresholds ranging from -1.5 to -8.0 were tested; differences were expressed as the odds ratio (OR) of a patient exceeding the threshold versus no change or deterioration. Results: The ORs measuring benefit of active treatment were similar across thresholds in short-term studies (LAB, ORs 1.40-1.42; LABA/ICS, 1.50-1.56) and medium-term LAB studies (ORs 1.34-1.43), whereas ORs in medium-term studies with LABA/ICS intervention showed a trend for higher response rates at higher values of threshold cut-points (1.64-1.79). In short-term studies, different thresholds had little effect on the OR between active drugs versus a trend for lower ORs with lower thresholds in medium-term studies. Conclusions: The OR for a treatment effect compared with placebo appears consistent across a range of responder cut-points. In medium-term trials, the treatment difference between active drugs suggests that use of a lower threshold would not increase the odds of observing a measured treatment difference.
Authors: Jørgen Vestbo; Julie Anne Anderson; Peter Mark Anthony Calverley; Bartolomé Celli; Gary Thomas Ferguson; Christine Jenkins; Julie Carol Yates; Paul Wyatt Jones Journal: Clin Respir J Date: 2011-01 Impact factor: 2.570
Authors: Richard Casaburi; Bartolome Celli; James Crapo; Gerard Criner; Thomas Croxton; Alasdair Gaw; Paul Jones; Nancy Kline-Leidy; David A Lomas; Debora Merrill; Michael Polkey; Stephen Rennard; Frank Sciurba; Ruth Tal-Singer; Robert Stockley; Gerry Turino; Jorgen Vestbo; John Walsh Journal: COPD Date: 2013-06 Impact factor: 2.409
Authors: Maggie Tabberer; Victoria S Benson; Heather Gelhorn; Hilary Wilson; Niklas Karlsson; Hana Müllerova; Shailendra Menjoge; Stephen I Rennard; Ruth Tal-Singer; Debora Merrill; Paul W Jones Journal: Chronic Obstr Pulm Dis Date: 2017-03-13
Authors: Peter M A Calverley; Julie A Anderson; Bartolome Celli; Gary T Ferguson; Christine Jenkins; Paul W Jones; Julie C Yates; Jørgen Vestbo Journal: N Engl J Med Date: 2007-02-22 Impact factor: 91.245
Authors: Donald P Tashkin; Bartolome Celli; Stephen Senn; Deborah Burkhart; Steven Kesten; Shailendra Menjoge; Marc Decramer Journal: N Engl J Med Date: 2008-10-05 Impact factor: 91.245
Authors: Paul W Jones; Kai M Beeh; Kenneth R Chapman; Marc Decramer; Donald A Mahler; Jadwiga A Wedzicha Journal: Am J Respir Crit Care Med Date: 2014-02-01 Impact factor: 21.405
Authors: Sandeep Bodduluri; Arie Nakhmani; Joseph M Reinhardt; Carla G Wilson; Merry-Lynn McDonald; Ramaraju Rudraraju; Byron C Jaeger; Nirav R Bhakta; Peter J Castaldi; Frank C Sciurba; Chengcui Zhang; Purushotham V Bangalore; Surya P Bhatt Journal: JCI Insight Date: 2020-07-09
Authors: Fernando J Martinez; Alvar Agusti; Bartolome R Celli; MeiLan K Han; James P Allinson; Surya P Bhatt; Peter Calverley; Sanjay H Chotirmall; Badrul Chowdhury; Patrick Darken; Carla A Da Silva; Gavin Donaldson; Paul Dorinsky; Mark Dransfield; Rosa Faner; David M Halpin; Paul Jones; Jerry A Krishnan; Nicholas Locantore; Fernando D Martinez; Hana Mullerova; David Price; Klaus F Rabe; Colin Reisner; Dave Singh; Jørgen Vestbo; Claus F Vogelmeier; Robert A Wise; Ruth Tal-Singer; Jadwiga A Wedzicha Journal: Am J Respir Crit Care Med Date: 2022-02-01 Impact factor: 21.405
Authors: Edward M Kerwin; Isabelle H Boucot; Claus F Vogelmeier; Francois Maltais; Ian P Naya; Lee Tombs; Paul W Jones; David A Lipson; Tom Keeley; Leif Bjermer Journal: Ther Adv Respir Dis Date: 2020 Jan-Dec Impact factor: 4.031